Candel Therapeutics Inc (CADL) FinancialsCADLCandel Therapeutics Inc

Evaluating the bottom line, Candel Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -81.84%, provide a clear picture of how effectively CADL converts its operational activities into shareholder value.

In the context of the broader market, CADL competes directly with industry leaders such as WVE and GERN. With a market capitalization of $896.80M, it holds a significant position in the sector. When comparing efficiency, CADL's gross margin of N/A stands against WVE's 100.00% and GERN's 94.94%. Such benchmarking helps identify whether Candel Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Candel Therapeutics has shown a significant increase in its stock price, with a YTD change of +140.26% and a 1-year change of +123.04%. Despite recent losses, the company has a strong current ratio of 28.05, indicating good short-term financial health.